Reply

Autor: Muthiah Vaduganathan, Scott D. Solomon, Peder L. Myhre, Paradigm-Hf Investigators

Publikováno v: Journal of the American College of Cardiology. 74:165-166

In our recent paper [(1)][1], we demonstrated that both B-type natriuretic peptide (BNP) and N-terminal pro-BNP at baseline and during treatment with angiotensin receptor-neprilysin inhibitor (ARNI) were found to be independently and comparably assoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9c5acea40c65aae9ad59e9b18200499
https://doi.org/10.1016/j.jacc.2019.05.006

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Autor: Mogensen, Ulrik M., Køber, Lars, Jhund, Pardeep S., Desai, Akshay S., Senni, Michele, Kristensen, Søren L., Dukát, Andrej, Chen, Chen‐Huan, Ramires, Felix, Lefkowitz, Martin P., Prescott, Margaret F., Shi, Victor C., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Packer, Milton, McMurray, John J. V., on behalf of the PARADIGM‐HF Investigators and Committees, Chen, Chen-Huan, PARADIGM-HF Investigators and Committees

Publikováno v: European Journal of Heart Failure; Mar2018, Vol. 20 Issue 3, p514-522, 9p, 4 Charts, 4 Graphs

Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization

Autor: Paradigm-Hf Investigators, Scott D. Solomon, Victor Shi, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, John J.V. McMurray, Randall C. Starling, Akshay S. Desai, Jean L. Rouleau, John R. Teerlink, Brian Claggett, Milton Packer

BACKGROUND Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. OBJECTIVES This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6676a364ad76501043a02cbf76e28937
https://eprints.gla.ac.uk/121532/1/121532.pdf

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Autor: Packer, Milton, Mcmurray, John J. V., Desai, Akshay S., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael, Andersen, Karl, Arango, Juan Luis, Arnold, J. Malcolm, Belohlávek, Jan, Böhm, Michael, Boytsov, Sergey, Burgess, Lesley J., Cabrera, Walter, Calvo, Carlos, Chen, Chen Huan, Dukat, Andrej, Duarte, Yan Carlos, Erglis, Andrejs, Michael, Fu, Gomez, Efrain, Gonzàlez Medina, Angel, Hagège, Albert A., Huang, Jun, Katova, Tzvetana, Kiatchoosakun, Songsak, Kim, Kee Sik, Kozan, Ömer, Llamas, Edmundo Bayram, Martinez, Felipe, Merkely, Bela, Mendoza, Iván, Mosterd, Arend, Negrusz Kawecka, Marta, Peuhkurinen, Keijo, Ramires, Felix J. A., Refsgaard, Jens, Rosenthal, Arvo, Senni, Michele, Sibulo, Antonio S., Silva Cardoso, José, Squire, Iain B., Starling, Randall C., Teerlink, John R., Vanhaecke, Johan, Vinereanu, Dragos, Wong, Raymond Ching Chiew, PARADIGM HF Investigators, Coordinators, Lembo, Giuseppe

Publikováno v: Circulation, 131, 54-61
CIRCULATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Circulation, 131(1), 54-61. United States (2015).
PARADIGM-HF Investigators and Coordinators 2015, ' Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure ', Circulation, vol. 131, no. 1, pp. 54-61 . https://doi.org/10.1161/CIRCULATIONAHA.114.013748
Circulation, 131, 1, pp. 54-61

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5086c07c21d92574fd696e862c242dc5
https://avesis.deu.edu.tr/publication/details/4078ddc0-b37b-4b3d-90b2-58d795356236/oai

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.